生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
SI-BONE, Inc.
Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application
2024-01-30
·
BioSpace
突破性疗法
SANTA CLARA, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) --
SI-BONE, Inc.
, (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving
musculoskeletal disorders
of the sacropelvic anatomy, announces FDA 510(k) premarket clearance of the iFuse Bedrock Granite® Implant System (Granite) in a smaller (9.5 mm) diameter with both an expanded indication in pediatric patients and an expanded application that includes use in the S1 trajectory. When placed across the SI joint, the Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for multi-segment spinal fusion. This 510(k) clearance follows the initial clearance of the iFuse Bedrock Granite System in May 2022 that included implants of 10.5 mm and 11.5 mm in diameter. The iFuse Bedrock Granite System was also awarded a Breakthrough Device Designation (BDD) by the
Food & Drug Administration (FDA)
and a New Technology Add-on Payment (NTAP) by the Centers for Medicare and Medicaid Services (CMS). According to Chris Shaffrey, MD, Chief of the Spine Division at
Duke University
, “The addition of a 9.5 mm diameter implant will seamlessly blend into my workflow, especially with both closed head and open head options. I’m very excited for patients to benefit from this breakthrough spinopelvic technology.” “With the expanded sacral indication and a smaller diameter Granite implant, I can utilize the Granite technology at S1, a segment which published literature has shown to be one of the most challenging segments in the spine, with reported screw loosening rates ranging from 16-41%,”1,2,3 said Brian A. O’Shaughnessy, MD, Reconstructive Spinal Surgeon at
Howell Allen Clinic
in Nashville, TN. Greg Mundis, MD, Orthopedic Spine Surgeon at Scripps Hospital mentions, “There is increasing interest among the surgeon community to include pelvic fixation in high-risk patients undergoing shorter (2-3 level) lumbar fusions. The addition of a 9.5 mm diameter to the
Granite
product line now offers surgeons one of the more commonly used sizes to treat these patients.” About
SI-BONE, Inc.
SI-BONE
(NASDAQ: SIBN) is a global leader in technology for surgical treatment of
musculoskeletal disorders
of the sacropelvic anatomy. Since pioneering minimally invasive surgery of the SI joint in 2009,
SI-BONE
has supported over 3,600 surgeons in performing a total of more than 95,000 sacropelvic procedures. A unique body of clinical evidence supports the use of
SI-BONE
’s technologies, including two randomized controlled trials and over 125 peer reviewed publications.
SI-BONE
has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including
adult deformity
, spinopelvic fixation, and
pelvic trauma
. For additional information on the company or the products including risks and benefits, please visit iFuse Bedrock Granite, iFuse-TORQ and
SI-BONE
are registered trademarks of
SI-BONE, Inc.
©2024
SI-BONE, Inc.
All Rights Reserved. Investor Contact: Saqib Iqbal investors@si-bone.com References Xu F, Zhou S, Zou D, Li W, Sun Z, Jiang S. The relationship between S1 screw loosening and postoperative outcome in patients with
degenerative lumbar scoliosis
. BMC Musculoskelet Disord. 2022 Feb 28;23(1):186. Kim JB, Park SW, Lee YS, et al. The effects of spinopelvic parameters and Paraspinal muscle degeneration on S1 screw loosening. J Korean Neurosurg Soc. 2015;58(4):357–362. Finger T, Bayerl S, Onken J, et al. Sacropelvic fixation versus fusion to the sacrum for spondylodesis in
multilevel degenerative spine disease
. Eur Spine J. 2014;23(5):1013–1020. A photo accompanying this announcement is available at: SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
SI-BONE, Inc.
US Food & Drug Administration
Duke University
[+1]
适应症
肌肉骨骼系统疾病
先天性畸形
创伤和损伤
[+2]
靶点
-
药物
GRANITE-001
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务